von Wolff Michael, Thaler Christian J, Frambach Torsten, Zeeb Cosima, Lawrenz Barbara, Popovici Roxana M, Strowitzki Thomas
Department of Gynecologic Endocrinology and Reproductive Medicine, Women's University Hospital, University of Heidelberg, Heidelberg, Germany.
Gynecologic Endocrinology and Reproductive Medicine, Women's Hospital, Ludwig-Maximilians-University of Munich, Campus Grosshadern, Grosshadern, Germany.
Fertil Steril. 2009 Oct;92(4):1360-1365. doi: 10.1016/j.fertnstert.2008.08.011. Epub 2008 Oct 18.
To analyze if oocytes can be obtained in all patients before cancer treatment within 2 weeks by initiating ovarian stimulation during the follicular or luteal phase.
Prospective controlled multicenter trial.
Four university-based centers.
PATIENT(S): Forty cancer patients before chemotherapy.
INTERVENTION(S): Twenty-eight patients were stimulated with gonadotropins in the follicular phase (group I). In 12 patients (group II), ovarian stimulation was initiated in the luteal phase, and these received GnRH antagonists and recombinant FSH. In 14 patients, 143 oocytes were further processed for fertilization by intracytoplasmic sperm injection (ICSI).
MAIN OUTCOME MEASURE(S): Number of oocytes aspirated after ovarian stimulation, cumulative FSH/hMG dosage, viability and maturity of oocytes, and fertilization rate by ICSI.
RESULT(S): Patients in group I (age 27.6 +/- 4.9 yrs) were stimulated on average for 10.6 days, and patients in group II (age 31.2 +/- 5.7 yrs) for 11.4 days. Total amount of FSH was on average 2,255 IU (I) and 2,720 IU (II) per patient. Average and median numbers of aspirated oocytes were, respectively, 13.1 and 11.5 (I) versus 10.0 and 8.5 (II); 83.7% (I) and 80.4% (II) of the oocytes were mature and viable and could be treated by ICSI. Fertilization rate was 61.0% (I) versus 75.6% (II).
CONCLUSION(S): This pilot study suggests that oocytes can be obtained before cancer treatment efficiently irrespective of the phase of the menstrual cycle.
分析在卵泡期或黄体期启动卵巢刺激,能否在癌症治疗前2周内使所有患者获取卵母细胞。
前瞻性对照多中心试验。
四个大学附属医院中心。
40例化疗前的癌症患者。
28例患者在卵泡期接受促性腺激素刺激(I组)。12例患者(II组)在黄体期启动卵巢刺激,接受促性腺激素释放激素拮抗剂和重组促卵泡素。14例患者的143枚卵母细胞进一步经卵胞浆内单精子注射(ICSI)进行受精处理。
卵巢刺激后吸出的卵母细胞数量、促卵泡素/人绝经期促性腺激素累积剂量、卵母细胞活力和成熟度以及ICSI受精率。
I组患者(年龄27.6±4.9岁)平均刺激10.6天,II组患者(年龄31.2±5.7岁)平均刺激11.4天。每位患者促卵泡素总量平均分别为2255IU(I组)和2720IU(II组)。吸出卵母细胞的平均数和中位数分别为13.1和11.5(I组),以及10.0和8.5(II组);83.7%(I组)和80.4%(II组)的卵母细胞成熟且有活力,可进行ICSI处理。受精率为61.0%(I组)对75.6%(II组)。
这项初步研究表明,无论月经周期处于哪个阶段,均可在癌症治疗前有效获取卵母细胞。